Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin
<strong>Background</strong>: Management of multiple sclerosis (MS) is based on the usage of immunosuppressive and immune-modulating medications. Cytokines play an important role in the pathogenesis of MS. <br/><strong>Objective</strong>: To evaluate the effects of rapam...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Shiraz University of Medical Sciences
2016-06-01
|
| Series: | Iranian Journal of Immunology |
| Subjects: | |
| Online Access: | http://iji.sums.ac.ir/article_16665_f83547dab1399dc9fa70a5c78f7fa04a.pdf |
| _version_ | 1818327273008267264 |
|---|---|
| author | Mansour Salehi Bahram Bagherpour Vahid Shayghannejad Farzaneh Mohebi Rasool Jafari |
| author_facet | Mansour Salehi Bahram Bagherpour Vahid Shayghannejad Farzaneh Mohebi Rasool Jafari |
| author_sort | Mansour Salehi |
| collection | DOAJ |
| description | <strong>Background</strong>: Management of multiple sclerosis (MS) is based on the usage of immunosuppressive and immune-modulating medications. Cytokines play an important role in the pathogenesis of MS. <br/><strong>Objective</strong>: To evaluate the effects of rapamycin on the concentrations of Th1/Th2/Th17 serum cytokines in patients with MS. <br/><strong>Methods</strong>: Six patients with relapsing remitting MS as a case group and 6 healthy individuals as a control group were enrolled. The patients have been receiving 2 mg rapamycin daily for 6 months. The individuals in control group received nothing during 6 months of the experiment. Enzyme linked immunosorbent assay (Simultaneous Multi-Analyte ELISA) technique was used for determination of serum concentrations of IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-γ, TNF-α, G-CSF and TGF-β before and after therapy with rapamycin. <br/><strong>Results</strong>: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-γ and TNF-α. The only statistically significant reduction was observed in the absorbance of IFN-γ (p=0.028). Two cytokines illustrated increase in the patients sera after the therapy, including G-CSF and TGF-β, but only increase in TGF-β was statistically significant (p=0.046). None of the studied cytokines in the control group varied significantly after 6 months. <br/><strong>Conclusion</strong>: Based on the findings of this study, rapamycin has some immunosuppressive effects, such as decreasing IFN-γ, which can improve the quality of life of the patients with multiple sclerosis. Also the increased level of TGF-β may also have benefits on the disease, which needs further clinical studies. |
| first_indexed | 2024-12-13T12:13:39Z |
| format | Article |
| id | doaj.art-52e4b3744c8e444cb8d7c464600a3dd0 |
| institution | Directory Open Access Journal |
| issn | 1735-1383 1735-367X |
| language | English |
| last_indexed | 2024-12-13T12:13:39Z |
| publishDate | 2016-06-01 |
| publisher | Shiraz University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Immunology |
| spelling | doaj.art-52e4b3744c8e444cb8d7c464600a3dd02022-12-21T23:46:46ZengShiraz University of Medical SciencesIranian Journal of Immunology1735-13831735-367X2016-06-0113214114716665Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with RapamycinMansour Salehi0Bahram Bagherpour1Vahid Shayghannejad2Farzaneh Mohebi3Rasool Jafari4Department of Genetics and Molecular Biology, School of Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Genetics and Molecular Biology, School of Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Neurology, School of Medicine, Isfahan University of Medical Sciences, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Microbiology, Islamic Azad University, School of Medicine, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran<strong>Background</strong>: Management of multiple sclerosis (MS) is based on the usage of immunosuppressive and immune-modulating medications. Cytokines play an important role in the pathogenesis of MS. <br/><strong>Objective</strong>: To evaluate the effects of rapamycin on the concentrations of Th1/Th2/Th17 serum cytokines in patients with MS. <br/><strong>Methods</strong>: Six patients with relapsing remitting MS as a case group and 6 healthy individuals as a control group were enrolled. The patients have been receiving 2 mg rapamycin daily for 6 months. The individuals in control group received nothing during 6 months of the experiment. Enzyme linked immunosorbent assay (Simultaneous Multi-Analyte ELISA) technique was used for determination of serum concentrations of IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-γ, TNF-α, G-CSF and TGF-β before and after therapy with rapamycin. <br/><strong>Results</strong>: The mean absorbance of 10 out of the 12 studied cytokines showed reduction after the therapy with rapamycin including IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17, IFN-γ and TNF-α. The only statistically significant reduction was observed in the absorbance of IFN-γ (p=0.028). Two cytokines illustrated increase in the patients sera after the therapy, including G-CSF and TGF-β, but only increase in TGF-β was statistically significant (p=0.046). None of the studied cytokines in the control group varied significantly after 6 months. <br/><strong>Conclusion</strong>: Based on the findings of this study, rapamycin has some immunosuppressive effects, such as decreasing IFN-γ, which can improve the quality of life of the patients with multiple sclerosis. Also the increased level of TGF-β may also have benefits on the disease, which needs further clinical studies.http://iji.sums.ac.ir/article_16665_f83547dab1399dc9fa70a5c78f7fa04a.pdfCytokine ProfileMultiple SclerosisRapamycin |
| spellingShingle | Mansour Salehi Bahram Bagherpour Vahid Shayghannejad Farzaneh Mohebi Rasool Jafari Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin Iranian Journal of Immunology Cytokine Profile Multiple Sclerosis Rapamycin |
| title | Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin |
| title_full | Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin |
| title_fullStr | Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin |
| title_full_unstemmed | Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin |
| title_short | Th1, Th2 and Th17 Cytokine Profile in Patients with Multiple Sclerosis Following Treatment with Rapamycin |
| title_sort | th1 th2 and th17 cytokine profile in patients with multiple sclerosis following treatment with rapamycin |
| topic | Cytokine Profile Multiple Sclerosis Rapamycin |
| url | http://iji.sums.ac.ir/article_16665_f83547dab1399dc9fa70a5c78f7fa04a.pdf |
| work_keys_str_mv | AT mansoursalehi th1th2andth17cytokineprofileinpatientswithmultiplesclerosisfollowingtreatmentwithrapamycin AT bahrambagherpour th1th2andth17cytokineprofileinpatientswithmultiplesclerosisfollowingtreatmentwithrapamycin AT vahidshayghannejad th1th2andth17cytokineprofileinpatientswithmultiplesclerosisfollowingtreatmentwithrapamycin AT farzanehmohebi th1th2andth17cytokineprofileinpatientswithmultiplesclerosisfollowingtreatmentwithrapamycin AT rasooljafari th1th2andth17cytokineprofileinpatientswithmultiplesclerosisfollowingtreatmentwithrapamycin |